Organization | China National Biotec Group Co., Ltd

China National Biotec Group Co., Ltd Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Lanzhou China (1934)

Organization Overview

First Clinical Trial

2009

NCT01336166

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Drugs in Phase 4 Trials (23)

Key: China National Biotec Group Co., Ltd (21) Acquired (2)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (5 trials)

bivalent oral polio vaccine (bopv), type 1 and type 3 (3 trials)

covax (4 trials)

covax-19 (4 trials)

covid-19 vaccine (vero cells) (4 trials)

dtap (5 trials)

ev71 vaccine (2 trials)

hepatitis a (live) vaccine (1 trial)

hepatitis a vaccine, inactivated (vaqta) (2 trials)

inactivated covid-19 vaccine (6 trials)

inactivated influenza vaccine (10 trials)

inactivated sabin strain polio virus (1 trial)

ipv (4 trials)

live attenuated chimeric japanese encephalitis vaccine (1 trial)

live attenuated varicella vaccine (7 trials)

live oral poliovirus type 1, 2 and 3 (3 trials)

measles, mumps and rubella vaccine (1 trial)

measles-rubella vaccine (1 trial)

mmr (3 trials)

multi-valent pneumococcal conjugate vaccine (1 trial)

sipv (1 trial)

split virion influenza vaccine (2 trials)

tivantinib (1 trial)

Drugs in Phase 3 Trials (9)

carboplatin (paraplatin) (1 trial)

docetaxel (taxotere) (1 trial)

haemophilus influenzae type b conjugate vaccine (PedvaxHIB) (1 trial)

inactivated SARS-Cov-2 vaccine (2 trials)

recombinant covid-19 vaccine (cho cell) (2 trials)

rimabotulinumtoxinB (Myobloc) (3 trials)

rituximab (rituxan) (1 trial)

tdap-ipv vaccine (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (7)

Key: China National Biotec Group Co., Ltd (5) Acquired (2)

aluminum hydroxide (Gaviscon) (3 trials)

cytokine induced killer cells (1 trial)

gamma-delta t cells (1 trial)

gi.1/gii.4 bivalent vlp vaccine (2 trials)

nvsi-06-08 (1 trial)

phosphate buffer (1 trial)

plague vaccine (1 trial)

Drugs in Phase 1 Trials (7)

Key: China National Biotec Group Co., Ltd (2) Acquired (5)

acyw135 mcv (1 trial)

anti-cd19-car gamma-delta t cells (1 trial)

autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells (1 trial)

bevacizumab (avastin) (1 trial)

cd19 car-t cells (1 trial)

muc1-gene-dc-ctl (1 trial)

muc1-peptide-dc-ctl (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Caliciviridae Infections (Phase 1)

Chickenpox (Phase 4)

Enterovirus Infections (Phase 4)

Foot-and-Mouth Disease (Phase 4)

Gastroenteritis (Phase 1)

Hand, Foot and Mouth Disease (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Herpes Zoster (Phase 4)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Meningitis (Phase 1)

Meningitis, Meningococcal (Phase 1)

Migraine Disorders (Phase 3)

Mouth Diseases (Phase 4)

Muscle Spasticity (Phase 3)

Plague (Phase 2)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 4)

Poliomyelitis (Phase 4)

Stroke (Phase 3)

Urinary Bladder, Overactive (Phase 3)

Virus Diseases (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 67
# of Trial APIs: 46